Tyra Biosciences announced positive initial results from its SURF302 Phase 2 study of oral dabogratinib for treating FGFR3-altered non-muscle invasive bladder cancer (NMIBC). The data demonstrated strong efficacy and a favorable safety profile, establishing a clinical proof of concept and identifying 60 mg once-daily as a potential dose for future registrational studies.
Key Details
- Efficacy Results: The 60 mg dose cohort (n=14) showed a 79% Overall Response Rate (ORR) and a 64% Best Overall Complete Response (CR) rate as of the August 31, 2026 data cutoff.
- Safety Profile: Dabogratinib was well-tolerated, with most adverse events being Grade 1 or 2. At the 60 mg dose, there were no dose reductions or treatment-related discontinuations.
- Next Steps: The company plans to engage with health authorities on a Phase 3 study design and expects to initiate a registrational adjuvant study in 2027.
- Market Opportunity: TYRA estimates the potential total market opportunity for this indication to be greater than $5 billion.